ExodusPoint Capital Management LP Makes New $356,000 Investment in Amedisys, Inc. (NASDAQ:AMED)

ExodusPoint Capital Management LP purchased a new stake in shares of Amedisys, Inc. (NASDAQ:AMED) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,923 shares of the health services provider’s stock, valued at approximately $356,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Blue Trust Inc. raised its holdings in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 124 shares during the last quarter. HBW Advisory Services LLC bought a new position in shares of Amedisys in the fourth quarter worth approximately $38,000. Versant Capital Management Inc increased its stake in shares of Amedisys by 68.5% in the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares in the last quarter. Vestcor Inc bought a new stake in shares of Amedisys during the 4th quarter valued at $73,000. Finally, Venturi Wealth Management LLC boosted its holdings in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock worth $89,000 after buying an additional 779 shares during the period. Institutional investors own 94.36% of the company’s stock.

Amedisys Stock Performance

Shares of NASDAQ:AMED opened at $91.51 on Friday. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $92.20 and a two-hundred day simple moving average of $92.05. The stock has a market capitalization of $3.00 billion, a P/E ratio of 36.31, a PEG ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The business had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. On average, analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Stephens reaffirmed an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $101.00.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.